5,7-dihydroxy-3,8-dimethoxyflavone | 33803-42-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,7-dihydroxy-3,8-dimethoxyflavone
• 英文别名: gnaphaliin；gnaphaliin A；5,7-dihydroxy-3,8-dimethoxy-2-phenylchromen-4-one
• CAS: 33803-42-8
• 化学式: C₁₇H₁₄O₆
• 分子量: 314.295
• InChiKey: OWQLBLNRUZULFV-UHFFFAOYSA-N

物化性质

• 熔点：
  145-148 °C
• 沸点：
  552.2±50.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY
  申请人：OSTEONEUROGEN INC.

  公开号：US20170239211A1

  公开（公告）日：2017-08-24

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

  一种药物组合物包含化学式1的咖啡酮衍生物和一种药用可接受的盐作为活性成分，从而有效抑制EMT的激活，从而使得能够有效抑制由于EMT激活而导致的器官或组织纤维化引起的疾病。
• Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity
  申请人：OSTEONEUROGEN INC.

  公开号：US10744114B2

  公开（公告）日：2020-08-18

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

  一种药物组合物含有化学式 1 的铬酮衍生物和药学上可接受的盐作为活性成分，从而有效抑制 EMT 的活化，从而能够有效抑制体内器官或组织因 EMT 活化而纤维化引起的疾病。
• Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity
  申请人：OSTEONEUROGEN INC.

  公开号：US10744113B2

  公开（公告）日：2020-08-18

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

  一种药物组合物含有化学式 1 的铬酮衍生物和药学上可接受的盐作为活性成分，从而有效抑制 EMT 的活化，从而能够有效抑制体内器官或组织因 EMT 活化而纤维化引起的疾病。
• NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY
  申请人：OSTEONEUROGEN INC.

  公开号：US20190231739A1

  公开（公告）日：2019-08-01

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.